AICLRs 31.0+9.1%BERGRs 36.5-14.4%PRLRs 147.7+44.2%AGLRs 16.9+69.1%KAPCORs 51.5+57.5%SITCRs 52.5-4.6%NMLRs 374.1+210.3%NETSOLRs 5,771.3+29.7%BOPRs 138.7-11.7%PSORs 443.1+105.3%NPLRs 18.7+89.3%FMLRs 288.6+94.9%MARIRs 23.5-11.0%THALLRs 140.6+110.3%NRLRs 61.3-22.3%HBLRs 451.9-6.7%SYSRs 1,566.1+36.2%GATMRs 79.9+33.4%GHGLRs 1,075.6+1.5%FCEPLRs 85.0+61.6%PNSCRs 566.1-42.5%AVNRs 463.8+57.3%FFLRs 135.5+33.3%AGTLRs 159.5-34.9%FEROZRs 274.0+45.3%SRVIRs 38.0+63.0%ILPRs 26.7+20.5%KELRs 71.8+64.8%MLCFRs 1.8-5.9%HTLRs 157.8+46.7%PIOCRs 54.6+58.7%IGIHLRs 98.5-4.8%EFERTRs 76.5+20.3%FFCRs 14.2-30.0%GHNIRs 476.1+34.4%PTCRs 14,713.1+1.5%TPLPRs 2,078.1+10.1%UBLRs 355.3-25.8%ISLRs 171.0+2.7%APLRs 38.3+9.0%ABOTRs 4.4-26.4%PKGSRs 61.2+35.3%FABLRs 263.0-1.9%ATLHRs 10.6-5.5%OGDCRs 71.0+43.4%MTLRs 106.9-27.7%NCLRs 5.7+56.9%UNITYRs 758.2+41.8%LUCKRs 67.7+22.9%KTMLRs 158.5+51.2%SNBLRs 172.8+16.1%BWCLRs 196.5+40.1%CHCCRs 25.0-4.0%ASTLRs 9.1+14.5%ITTEFAQRs 12.3-9.9%AGPRs 30.8-42.3%HINOONRs 61.3-35.9%ENGRORs 68.6+46.4%ATRLRs 26.4+81.9%SHELRs 187.1-5.4%JDWSRs 2.1+20.6%EFUGRs 50.9+44.1%KOHCRs 79.1+42.0%BNWMRs 54.3+62.8%GLAXORs 56.9+14.0%CNERGYRs 49.2-1.8%JSBLRs 377.8-24.1%SEARLRs 21.7-21.2%MCBRs 81.8-4.4%BAFLRs 110.1+14.1%TGLRs 236.2-8.1%NCPLRs 27.7+19.9%AIRLINKRs 81.3+23.7%PAELRs 27.5+77.4%PAKTRs 1.7+3.6%INDURs 74.3-34.6%EPCLRs 17.8-50.1%TRGRs 100.9+18.5%SNGPRs 3.6-7.2%MEBLRs 95.1+11.0%PPLRs 12.0+27.2%POLRs 149.8+69.1%BAHLRs 123.3-17.6%GWLCRs 18.0+9.8%ACPLRs 41.8+19.4%FCCLRs 146.4+6.4%HCARRs 752.9-10.6%NBPRs 173.6-16.9%FATIMARs 237.9+68.5%SSGCRs 12.9+40.7%AKBLRs 268.1-10.1%LOTCHEMRs 65.9-7.3%NATFRs 5.0-57.8%MUGHALRs 76.8-47.2%PSMCRs 514.2-32.5%ICIRs 268.1+5.8%HUBCRs 48.3+16.8%NESTLERs 4.6-50.6%ARPLRs 89.9-12.9%DGKCRs 681.9+39.9%PSELRs 113.5-0.4%AICLRs 31.0+9.1%BERGRs 36.5-14.4%PRLRs 147.7+44.2%AGLRs 16.9+69.1%KAPCORs 51.5+57.5%SITCRs 52.5-4.6%NMLRs 374.1+210.3%NETSOLRs 5,771.3+29.7%BOPRs 138.7-11.7%PSORs 443.1+105.3%NPLRs 18.7+89.3%FMLRs 288.6+94.9%MARIRs 23.5-11.0%THALLRs 140.6+110.3%NRLRs 61.3-22.3%HBLRs 451.9-6.7%SYSRs 1,566.1+36.2%GATMRs 79.9+33.4%GHGLRs 1,075.6+1.5%FCEPLRs 85.0+61.6%PNSCRs 566.1-42.5%AVNRs 463.8+57.3%FFLRs 135.5+33.3%AGTLRs 159.5-34.9%FEROZRs 274.0+45.3%SRVIRs 38.0+63.0%ILPRs 26.7+20.5%KELRs 71.8+64.8%MLCFRs 1.8-5.9%HTLRs 157.8+46.7%PIOCRs 54.6+58.7%IGIHLRs 98.5-4.8%EFERTRs 76.5+20.3%FFCRs 14.2-30.0%GHNIRs 476.1+34.4%PTCRs 14,713.1+1.5%TPLPRs 2,078.1+10.1%UBLRs 355.3-25.8%ISLRs 171.0+2.7%APLRs 38.3+9.0%ABOTRs 4.4-26.4%PKGSRs 61.2+35.3%FABLRs 263.0-1.9%ATLHRs 10.6-5.5%OGDCRs 71.0+43.4%MTLRs 106.9-27.7%NCLRs 5.7+56.9%UNITYRs 758.2+41.8%LUCKRs 67.7+22.9%KTMLRs 158.5+51.2%SNBLRs 172.8+16.1%BWCLRs 196.5+40.1%CHCCRs 25.0-4.0%ASTLRs 9.1+14.5%ITTEFAQRs 12.3-9.9%AGPRs 30.8-42.3%HINOONRs 61.3-35.9%ENGRORs 68.6+46.4%ATRLRs 26.4+81.9%SHELRs 187.1-5.4%JDWSRs 2.1+20.6%EFUGRs 50.9+44.1%KOHCRs 79.1+42.0%BNWMRs 54.3+62.8%GLAXORs 56.9+14.0%CNERGYRs 49.2-1.8%JSBLRs 377.8-24.1%SEARLRs 21.7-21.2%MCBRs 81.8-4.4%BAFLRs 110.1+14.1%TGLRs 236.2-8.1%NCPLRs 27.7+19.9%AIRLINKRs 81.3+23.7%PAELRs 27.5+77.4%PAKTRs 1.7+3.6%INDURs 74.3-34.6%EPCLRs 17.8-50.1%TRGRs 100.9+18.5%SNGPRs 3.6-7.2%MEBLRs 95.1+11.0%PPLRs 12.0+27.2%POLRs 149.8+69.1%BAHLRs 123.3-17.6%GWLCRs 18.0+9.8%ACPLRs 41.8+19.4%FCCLRs 146.4+6.4%HCARRs 752.9-10.6%NBPRs 173.6-16.9%FATIMARs 237.9+68.5%SSGCRs 12.9+40.7%AKBLRs 268.1-10.1%LOTCHEMRs 65.9-7.3%NATFRs 5.0-57.8%MUGHALRs 76.8-47.2%PSMCRs 514.2-32.5%ICIRs 268.1+5.8%HUBCRs 48.3+16.8%NESTLERs 4.6-50.6%ARPLRs 89.9-12.9%DGKCRs 681.9+39.9%PSELRs 113.5-0.4%

Compare Watch

FEROZ

BUY

Ferozsons Laboratories

Pharmaceuticals · 0.15% of the KSE-100

Price

Rs 273.95

Market cap

Rs 17.4bn

12-month return

+45.3%

Rank

25 of 101

61composite

Rule-based53

ML ranker75

Conviction81

Why the engine ranks it here

Ferozsons Laboratories (FEROZ) screens as attractive relative to the rest of the KSE-100, ranking 25 of 101 on a composite score of 61/100.

Ferozsons Laboratories sits in the Pharmaceuticals sector and scores best on growth (67/100), weakest on valuation (22/100). At PKR 273.95 the shares trade on a P/E of 2.1x, 0.53x book, a 11.0% dividend yield. The Piotroski F-Score is 8 of 9 (very strong) and the Altman Z''-Score is 8.89 (financially sound).

What it does well

FEROZ converts its asset base into profit efficiently at 15.0%.

Profitability & earnings quality

FEROZ grew revenue 21.5% over the last year.

Growth

FEROZ has compounded revenue at 18.7% a year over three years.

Growth

What holds it back

FEROZ offers only a 48.2% earnings yield.

Valuation

FEROZ pays little income at a 11.0% yield.

Valuation

FEROZ trades on 2.1x earnings, expensive against its sector.

Valuation

What would change this view

→ a pull-back in the share price, or earnings catching up with the current multiple

Five-pillar breakdown

Each pillar scores the company against sector peers, where 50 is the sector average.

Profitability & earnings quality30% weight64

Valuation25% weight22

Balance-sheet strength20% weight63

Growth15% weight67

Price trend10% weight61

The classic screens

Piotroski tests nine accounting facts about improvement; Altman scores the distance from financial distress.

Piotroski F-Score

8 / 9

very strong · 8 of 9 tests passed

Altman Z''-Score

8.89

safe zone · safe above 5.85

Profitable on assets

ROA 15.0%

Cash generative

CFO PKR 7,493m

Returns improving

ROA 15.0% vs 11.7% a year ago

Earnings backed by cash

CFO PKR 7,493m vs profit PKR 8,390m

Deleveraging

debt/assets 0.21 vs 0.22

Liquidity improving

current ratio 1.79 vs 1.71

Margin expanding

gross margin 37.2% vs 33.2%

Assets working harder

asset turnover 1.87x vs 1.83x

No shareholder dilution

64m shares vs 64m

Altman components

Working capital / assets0.220

Retained earnings / assets0.510

Operating profit / assets0.201

Equity / liabilities1.125

Sales / assets1.697

Price history

Weekly closes. Beta 0.60 against the index, annualised volatility 27%, RSI 70.

+1,169.5% over this window

Reported accounts

The last twelve quarters as filed, in PKR millions. The publication date is what the engine uses to decide when a figure became knowable.

Quarter	Revenue	Gross profit	Operating	Net income	EPS	Filed
2025 Q4	Rs 28.0bn	Rs 8.6bn	Rs 2.6bn	Rs 1.7bn	27.30	2026-04-30
2025 Q3	Rs 27.7bn	Rs 11.1bn	Rs 3.6bn	Rs 2.5bn	39.03	2025-11-14
2025 Q2	Rs 27.7bn	Rs 12.1bn	Rs 4.0bn	Rs 2.8bn	43.60	2025-08-14
2025 Q1	Rs 26.5bn	Rs 9.3bn	Rs 2.9bn	Rs 2.0bn	31.02	2025-05-15
2024 Q4	Rs 22.8bn	Rs 6.3bn	Rs 1.8bn	Rs 1.2bn	18.48	2025-04-30
2024 Q3	Rs 21.5bn	Rs 8.1bn	Rs 2.6bn	Rs 1.7bn	26.12	2024-11-14
2024 Q2	Rs 21.9bn	Rs 7.5bn	Rs 2.4bn	Rs 1.4bn	22.80	2024-08-14
2024 Q1	Rs 21.5bn	Rs 4.3bn	Rs 1.0bn	Rs 533m	8.39	2024-05-15
2023 Q4	Rs 21.3bn	Rs 8.8bn	Rs 2.9bn	Rs 1.9bn	29.17	2024-04-29
2023 Q3	Rs 20.2bn	Rs 5.9bn	Rs 1.7bn	Rs 1.0bn	16.40	2023-11-14
2023 Q2	Rs 20.6bn	Rs 6.6bn	Rs 2.0bn	Rs 1.3bn	19.74	2023-08-14
2023 Q1	Rs 19.8bn	Rs 7.0bn	Rs 2.2bn	Rs 1.4bn	22.31	2023-05-15

Ranked against Pharmaceuticals

Every peer in the same sector, ordered by composite score. These are the companies whose ratios set this one's z-scores.

FEROZFerozsons Laboratories2.1x61

ABOTAbbott Laboratories Pakistan0.4x55

AGPAGP Limited0.4x50

HINOONHighnoon Laboratories0.5x50

GLAXOGlaxoSmithKline Pakistan0.5x48

SEARLThe Searle Company0.5x46

Scored as of 31 December 2025. Generated by an automated screen for research and educational use. Not investment advice, and not a substitute for a SECP-licensed adviser.